Skip to main content
. Author manuscript; available in PMC: 2011 Sep 10.
Published in final edited form as: Mol Cell. 2010 Sep 10;39(5):761–772. doi: 10.1016/j.molcel.2010.08.013

Figure 6. MiR-200b Expression or Suz12 Inhibition in Combination with Chemotherapy Prevents Tumor Relapse.

Figure 6

(A) Tumor incidence in nude mice injected with CSCs from ER-Src transformed cells that were pre-treated with miR-200b or siRNA against Suz12 for 8h.

(B) Tumor volume (mm3) in xenografts treated with doxorubicin, miR-200b, siSuz12#2 and combinations at days 10, 15, 20, and 25.

(C) Percentage of CSCs derived from ER-Src tumors treated with doxorubicin combined with miR-200b or siSuz12.

(D) Expression of the indicated RNAs (mean ± SD) in CD44high/CD24low cells taken from tumors at day 25 treated as indicated.